Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2019 second quarter results announcement
We announced our second quarter results for the period ended 30 June 2019 on Wednesday 24 July.
Latest information
Latest press releases
- Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
- GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
- GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Annual Report 2018
We published our Annual Report 2018 on 12 March 2019. View the summary and download the full report or individual sections.